BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009; 15(11): 1301-1314 [PMID: 19294759 DOI: 10.3748/wjg.15.1301] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 87] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Kang SH, Kim do Y, Jeon SM, Ahn SH, Park JY, Kim SU, Kim JK, Lee KS, Chon CY, Han KH. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. Eur J Gastroenterol Hepatol. 2012;24:849-856. [PMID: 22495400 DOI: 10.1097/meg.0b013e3283535c34] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
2 Holmila R, Sklias A, Muller DC, Degli Esposti D, Guilloreau P, Mckay J, Sangrajrang S, Srivatanakul P, Hainaut P, Merle P, Herceg Z, Nogueira da Costa A. Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma. PLoS One 2017;12:e0174265. [PMID: 28333958 DOI: 10.1371/journal.pone.0174265] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
3 Rau KM, Liu CT, Hsiao YC, Hsiao KY, Wang TM, Hung WS, Su YL, Liu WC, Wang CH, Hsu HL, Chuang PH, Cheng JC, Tseng CP. Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response. J Clin Med. 2020;9. [PMID: 32071283 DOI: 10.3390/jcm9010188] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
4 Shehata F, Abdel Monem N, Sakr M, Kasem S, Balbaa M. Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma. Med Oncol 2013;30:673. [PMID: 23912699 DOI: 10.1007/s12032-013-0673-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
5 Özdemir F, Baskiran A. The Importance of AFP in Liver Transplantation for HCC. J Gastrointest Canc 2020;51:1127-32. [DOI: 10.1007/s12029-020-00486-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Kaido T, Ogawa K, Mori A, Fujimoto Y, Ito T, Tomiyama K, Takada Y, Uemoto S. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery. 2013;154:1053-1060. [PMID: 24074704 DOI: 10.1016/j.surg.2013.04.056] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 8.3] [Reference Citation Analysis]
7 Ahn YH, Ji ES, Shin PM, Kim KH, Kim YS, Ko JH, Yoo JS. A multiplex lectin-channel monitoring method for human serum glycoproteins by quantitative mass spectrometry. Analyst 2012;137:691-703. [PMID: 22158852 DOI: 10.1039/c1an15775b] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Xu XF, Liang L, Xing H, Shen F, Huang DS, Lau WY, Yang T. Clinical utility of serum biomarkers for hepatocellular carcinoma. Biomark Med 2021;15:151-5. [PMID: 33470867 DOI: 10.2217/bmm-2020-0474] [Reference Citation Analysis]
9 Sofocleous CT, Sideras P, Petre EN. “How we do it” - a practical approach to hepatic metastases ablation techniques. Tech Vasc Interv Radiol. 2013;16:219-229. [PMID: 24238377 DOI: 10.1053/j.tvir.2013.08.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
10 El Mahdy HA, Abdelhamid IA, Amen AI, Abdelsameea E, Hassouna MM. MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2019;20:2723-31. [PMID: 31554369 DOI: 10.31557/APJCP.2019.20.9.2723] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
11 Hsieh SY, He JR, Yu MC, Lee WC, Chen TC, Lo SJ, Bera R, Sung CM, Chiu CT. Secreted ERBB3 isoforms are serum markers for early hepatoma in patients with chronic hepatitis and cirrhosis. J Proteome Res 2011;10:4715-24. [PMID: 21877752 DOI: 10.1021/pr200519q] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
12 McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis. 2010;14:461-476. [PMID: 20638025 DOI: 10.1016/j.cld.2010.05.009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
13 Lin ZY, Wu CC, Chuang YH, Chuang WL. Clinical utility of a simple primary culture method in hepatocellular carcinoma patients. J Gastroenterol Hepatol 2015;30:352-7. [PMID: 25087586 DOI: 10.1111/jgh.12693] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
14 Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48. [PMID: 20207771 DOI: 10.1373/clinchem.2009.133124] [Cited by in Crossref: 146] [Cited by in F6Publishing: 119] [Article Influence: 12.2] [Reference Citation Analysis]
15 Waqar W, Asghar S, Manzoor S. Platelets' RNA as biomarker trove for differentiation of early-stage hepatocellular carcinoma from underlying cirrhotic nodules. PLoS One 2021;16:e0256739. [PMID: 34469466 DOI: 10.1371/journal.pone.0256739] [Reference Citation Analysis]
16 Becq A, Mateescu C, Khayat D, Bouattour M. Atypical Presentation of Hepatocellular Carcinoma Mimicking a Gastric Hepatoid Adenocarcinoma: A Case Report. Medicine (Baltimore) 2015;94:e1101. [PMID: 26166099 DOI: 10.1097/MD.0000000000001101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Ismail MH. Glypican-3-Expressing Hepatocellular Carcinoma in a Non-Cirrhotic Patient with Nonalcoholic Steatohepatitis: Case Report and Literature Review. Gastroenterology Res 2010;3:223-8. [PMID: 27957002 DOI: 10.4021/gr224w] [Reference Citation Analysis]
18 Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16:859-70. [PMID: 26095784 DOI: 10.1016/S1470-2045(15)00050-9] [Cited by in Crossref: 419] [Cited by in F6Publishing: 246] [Article Influence: 59.9] [Reference Citation Analysis]
19 Liu CC, Yang H, Zhang R, Zhao JJ, Hao DJ. Tumour-associated antigens and their anti-cancer applications. Eur J Cancer Care (Engl). 2017;26. [PMID: 26853428 DOI: 10.1111/ecc.12446] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
20 Na K, Kim M, Kim CY, Lim JS, Cho JY, Shin H, Lee HJ, Kang BJ, Han DH, Kim H, Baik JH, Swiatek-de Lange M, Karl J, Paik YK. Potential Regulatory Role of Human-Carboxylesterase-1 Glycosylation in Liver Cancer Cell Growth. J Proteome Res 2020;19:4867-83. [PMID: 33206527 DOI: 10.1021/acs.jproteome.0c00787] [Reference Citation Analysis]
21 Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol 2015; 7(12): 1632-1651 [PMID: 26140083 DOI: 10.4254/wjh.v7.i12.1632] [Cited by in Crossref: 120] [Cited by in F6Publishing: 107] [Article Influence: 17.1] [Reference Citation Analysis]
22 Zhu J, Jiang F, Ni HB, Xiao MB, Chen BY, Ni WK, Lu CH, Ni RZ. Combined analysis of serum γ-glutamyl transferase isoenzyme II, α-L-fucosidase and α-fetoprotein detected using a commercial kit in the diagnosis of hepatocellular carcinoma. Exp Ther Med. 2013;5:89-94. [PMID: 23251247 DOI: 10.3892/etm.2012.783] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
23 Waly Raphael S, Yangde Z, Yuxiang C. Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol 2012;2012:421673. [PMID: 22655206 DOI: 10.5402/2012/421673] [Cited by in Crossref: 25] [Cited by in F6Publishing: 45] [Article Influence: 2.5] [Reference Citation Analysis]
24 Ogawa K, Kaido T, Okajima H, Fujimoto Y, Yoshizawa A, Yagi S, Hori T, Iida T, Takada Y, Uemoto S. Impact of pretreatments on outcomes after living donor liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2019;26:73-81. [PMID: 30561147 DOI: 10.1002/jhbp.602] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
25 Ji ES, Hwang H, Park GW, Lee JY, Lee HK, Choi NY, Jeong HK, Kim KH, Kim JY, Lee S, Ahn YH, Yoo JS. Analysis of fucosylation in liver-secreted N-glycoproteins from human hepatocellular carcinoma plasma using liquid chromatography with tandem mass spectrometry. Anal Bioanal Chem 2016;408:7761-74. [PMID: 27565792 DOI: 10.1007/s00216-016-9878-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
26 da Costa AN, Plymoth A, Santos-Silva D, Ortiz-Cuaran S, Camey S, Guilloreau P, Sangrajrang S, Khuhaprema T, Mendy M, Lesi OA. Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. Int J Cancer. 2015;136:172-181. [PMID: 24803312 DOI: 10.1002/ijc.28953] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
27 Yang H, Xiong F, Qi R, Liu Z, Lin M, Rui J, Su J, Zhou R. LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. J Surg Oncol 2010;101:363-9. [DOI: 10.1002/jso.21489] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
28 Kobayashi S, Nouso K, Kinugasa H, Takeuchi Y, Tomoda T, Miyahara K, Hagihara H, Kuwaki K, Onishi H, Nakamura S, Ikeda F, Miyake Y, Shiraha H, Takaki A, Yamamoto K. Clinical utility of serum fucosylated hemopexin in Japanese patients with hepatocellular carcinoma: Fucosylated hemopexin and HCC. Hepatology Research 2012;42:1187-95. [DOI: 10.1111/j.1872-034x.2012.01044.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
29 Krishnamurthy S, Gilot D, Ahn SB, Lam V, Shin JS, Guillemin GJ, Heng B. Involvement of Kynurenine Pathway in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5180. [PMID: 34680327 DOI: 10.3390/cancers13205180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Ishihara T, Fukuda I, Morita A, Takinami Y, Okamoto H, Nishimura S, Numata Y. Development of quantitative plasma N-glycoproteomics using label-free 2-D LC-MALDI MS and its applicability for biomarker discovery in hepatocellular carcinoma. J Proteomics 2011;74:2159-68. [PMID: 21704746 DOI: 10.1016/j.jprot.2011.06.010] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
31 Brito AF, Mendes M, Abrantes AM, Tralhão JG, Botelho MF. Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)Fluoro-D-Glucose. Mol Diagn Ther 2014;18:495-504. [PMID: 24852041 DOI: 10.1007/s40291-014-0106-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
32 Qu KZ, Zhang K, Ma W, Li H, Wang X, Zhang X, Giles F, Lai M, Afdhal NH, Albitar M. Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease: Serum proteasomes and hepatocellular cancer. Journal of Gastroenterology and Hepatology 2011;26:751-8. [DOI: 10.1111/j.1440-1746.2010.06491.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
33 Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Review of Gastroenterology & Hepatology 2014;3:353-67. [DOI: 10.1586/egh.09.35] [Cited by in Crossref: 197] [Cited by in F6Publishing: 194] [Article Influence: 24.6] [Reference Citation Analysis]
34 Braicu C, Burz C, Berindan-Neagoe I, Balacescu O, Graur F, Cristea V, Irimie A. Hepatocellular Carcinoma: Tumorigenesis and Prediction Markers. Gastroenterology Res 2009;2:191-9. [PMID: 27942274 DOI: 10.4021/gr2009.07.1304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
35 Jurewicz E, Kasacka I, Bańkowski E, Filipek A. Identification and localization of S100A6 in human umbilical cord. Cell Biol Int 2012;36:109-12. [DOI: 10.1042/cbi20110233] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
36 De J, Shen Y, Qin J, Feng L, Wang Y, Yang L. A Systematic Review of Des-γ-Carboxy Prothrombin for the Diagnosis of Primary Hepatocellular Carcinoma. Medicine (Baltimore). 2016;95:e3448. [PMID: 27124038 DOI: 10.1097/md.0000000000003448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Becker-Weidman DJ, Kalb B, Sharma P, Kitajima HD, Lurie CR, Chen Z, Spivey JR, Knechtle SJ, Hanish SI, Adsay NV. Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging--comparison to prior same-center results after MR systems improvements. Radiology. 2011;261:824-833. [PMID: 21969663 DOI: 10.1148/radiol.11110157] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
38 Witjes CD, van Aalten SM, Steyerberg EW, Borsboom GJ, de Man RA, Verhoef C, Ijzermans JN. Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int. 2013;7:59-64. [PMID: 23519638 DOI: 10.1007/s12072-012-9374-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
39 Salama HM, Abdel-Haleem H, Taha FM, Abdel-Azeez RA, Marzaban RN, El-Nahaas SM, Darwish T. Plasma proteosome level as a potential marker for hepatocellular carcinoma. Arab J Gastroenterol 2013;14:87-93. [PMID: 24206735 DOI: 10.1016/j.ajg.2013.09.002] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 El-Tonsy MM, Hussein HM, Helal Tel-S, Tawfik RA, Koriem KM, Hussein HM. Schistosoma mansoni infection: is it a risk factor for development of hepatocellular carcinoma? Acta Trop 2013;128:542-7. [PMID: 23932944 DOI: 10.1016/j.actatropica.2013.07.024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
41 du Preez I, Sithebe NP. The use of metabolomics as a tool to investigate hepatitis C. Metabolomics 2013;9:497-505. [DOI: 10.1007/s11306-012-0467-8] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
42 Lin MT, Chen CL, Wang CC, Cheng YF, Eng HL, Wang JH, Chiu KW, Lee CM, Hu TH. Diagnostic sensitivity of hepatocellular carcinoma imaging and its application to non-cirrhotic patients. J Gastroenterol Hepatol 2011;26:745-50. [PMID: 21418303 DOI: 10.1111/j.1440-1746.2010.06501.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
43 Bridges JF, Gallego G, Blauvelt BM. Controlling liver cancer internationally: A qualitative study of clinicians' perceptions of current public policy needs. Health Res Policy Syst 2011;9:32. [PMID: 21798002 DOI: 10.1186/1478-4505-9-32] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
44 Ha Y, Shim JH, Kim SO, Kim KM, Lim YS, Lee HC. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. J Gastroenterol Hepatol. 2014;29:787-793. [PMID: 24224567 DOI: 10.1111/jgh.12452] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
45 Fan N, Li P, Zhou Y, Wu C, Wang X, Liu Z, Tang B. Demystifying Lysosomal α-l-Fucosidase in Liver Cancer-Bearing Mice by Specific Two-Photon Fluorescence Imaging. ACS Sens 2021. [PMID: 34968045 DOI: 10.1021/acssensors.1c01630] [Reference Citation Analysis]
46 Holmes E, Wijeyesekera A, Taylor-Robinson SD, Nicholson JK. The promise of metabolic phenotyping in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 2015;12:458-71. [PMID: 26194948 DOI: 10.1038/nrgastro.2015.114] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 5.6] [Reference Citation Analysis]
47 Kaido T, Morita S, Tanaka S, Ogawa K, Mori A, Hatano E, Uemoto S. Long-term outcomes of hepatic resection versus living donor liver transplantation for hepatocellular carcinoma: a propensity score-matching study. Dis Markers 2015;2015:425926. [PMID: 25922554 DOI: 10.1155/2015/425926] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
48 Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Kudo M, Pfiffer T, Hatano E, Chung HC, Kopeckova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Hsu Y, Abada PB, Zhu AX. Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. Br J Cancer 2018;119:19-26. [PMID: 29808014 DOI: 10.1038/s41416-018-0103-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
49 Rajoria S, Rani S, Chaudhari D, Jain S, Gupta U. Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib. Pharm Res 2019;36:160. [PMID: 31520196 DOI: 10.1007/s11095-019-2686-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
50 McCarley JR, Soulen MC. Percutaneous ablation of hepatic tumors. Semin Intervent Radiol. 2010;27:255-260. [PMID: 22550364 DOI: 10.1055/s-0030-1261783] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
51 Cui H, Wu F, Sun Y, Fan G, Wang Q. Up-regulation and subcellular localization of hnRNP A2/B1 in the development of hepatocellular carcinoma. BMC Cancer 2010;10:356. [PMID: 20604928 DOI: 10.1186/1471-2407-10-356] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
52 Smajerova M, Petrasova H, Little J, Ovesna P, Andrasina T, Valek V, Nemcova E, Miklosova B. Contrast-enhanced ultrasonography in the evaluation of incidental focal liver lesions: A cost-effectiveness analysis. World J Gastroenterol 2016; 22(38): 8605-8614 [PMID: 27784973 DOI: 10.3748/wjg.v22.i38.8605] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
53 Hong YM, Yoon KT, Cho M. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma. BMC Cancer 2021;21:569. [PMID: 34006248 DOI: 10.1186/s12885-021-08124-9] [Reference Citation Analysis]
54 Grieb BC, Goff LW, Goyal L, Denlinger CS. Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. Am Soc Clin Oncol Educ Book 2019;39:248-60. [PMID: 31099615 DOI: 10.1200/EDBK_237555] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
55 Wu CS, Lee TY, Chou RH, Yen CJ, Huang WC, Wu CY, Yu YL. Development of a highly sensitive glycan microarray for quantifying AFP-L3 for early prediction of hepatitis B virus-related hepatocellular carcinoma. PLoS One. 2014;9:e99959. [PMID: 24927126 DOI: 10.1371/journal.pone.0099959] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
56 Abd El Moety HA, Maharem DA, Gomaa SH. Serotonin: is it a marker for the diagnosis of hepatocellular carcinoma in cirrhotic patients? Alexandria Journal of Medicine 2013;49:369-78. [DOI: 10.1016/j.ajme.2013.03.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Hamdy K, Al Swaff R, Hussein HA, Gamal M. Assessment of serum adiponectin in Egyptian patients with HCV-related cirrhosis and hepatocellular carcinoma. J Endocrinol Invest 2015;38:1225-31. [PMID: 26359143 DOI: 10.1007/s40618-015-0379-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
58 Marrero JA, Kudo M, Bronowicki JP. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist. 2010;15 Suppl 4:23-33. [PMID: 21115578 DOI: 10.1634/theoncologist.2010-s4-23] [Cited by in Crossref: 79] [Cited by in F6Publishing: 47] [Article Influence: 7.2] [Reference Citation Analysis]
59 Li B, Li B, Guo T, Sun Z, Li X, Li X, Wang H, Chen W, Chen P, Mao Y. The Clinical Values of Serum Markers in the Early Prediction of Hepatocellular Carcinoma. Biomed Res Int. 2017;2017:5358615. [PMID: 28540298 DOI: 10.1155/2017/5358615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
60 Ahn YH, Kim JY, Yoo JS. Quantitative mass spectrometric analysis of glycoproteins combined with enrichment methods. Mass Spectrom Rev. 2015;34:148-165. [PMID: 24889823 DOI: 10.1002/mas.21428] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
61 Lee KA, Ahn JY, Lee SH, Singh Sekhon S, Kim DG, Min J, Kim YH. Aptamer-based Sandwich Assay and its Clinical Outlooks for Detecting Lipocalin-2 in Hepatocellular Carcinoma (HCC). Sci Rep 2015;5:10897. [PMID: 26039737 DOI: 10.1038/srep10897] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
62 Hu L, Yao W, Wang F, Rong X, Peng T. GP73 is upregulated by hepatitis C virus (HCV) infection and enhances HCV secretion. PLoS One. 2014;9:e90553. [PMID: 24608522 DOI: 10.1371/journal.pone.0090553] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
63 Ahn YH, Shin PM, Ji ES, Kim H, Yoo JS. A lectin-coupled, multiple reaction monitoring based quantitative analysis of human plasma glycoproteins by mass spectrometry. Anal Bioanal Chem 2012;402:2101-12. [DOI: 10.1007/s00216-011-5646-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
64 Yang H, Chen G, Fang F, Liu Z, Hiu Yan Lau S, Zhang J, Lau WY, Yang L. Dickkopf-1: As a Diagnostic and Prognostic Serum Marker for Early Hepatocellular Carcinoma. Int J Biol Markers 2013;28:286-97. [DOI: 10.5301/jbm.5000015] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
65 Shi M, Chen MS, Sekar K, Tan CK, Ooi LL, Hui KM. A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma. Eur J Cancer. 2014;50:928-936. [PMID: 24332572 DOI: 10.1016/j.ejca.2013.11.026] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
66 Ibrahim GH, Mahmoud MA, Aly NM. Evaluation of circulating Transforming growth factor-beta1, Glypican-3 and Golgi protein-73 mRNAs expression as predictive markers for hepatocellular carcinoma in Egyptian patients. Mol Biol Rep. 2013;40:7069-7075. [PMID: 24186850 DOI: 10.1007/s11033-013-2829-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
67 Ahn YH, Ji ES, Oh NR, Kim YS, Ko JH, Yoo JS. Differential proteomic approach for identification and verification of aberrantly glycosylated proteins in adenocarcinoma lung cancer (ADLC) plasmas by lectin-capturing and targeted mass spectrometry. J Proteomics 2014;106:221-9. [PMID: 24780727 DOI: 10.1016/j.jprot.2014.04.031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
68 Fehér J, Lengyel G. [Hepatocellular carcinoma: occurrence, risk factors, biomarkers]. Orv Hetil 2010;151:933-40. [PMID: 20494888 DOI: 10.1556/OH.2010.28900] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
69 Kamo N, Kaido T, Yagi S, Okajima H, Uemoto S. Liver transplantation for small hepatocellular carcinoma. Hepatobiliary Surg Nutr 2016;5:391-8. [PMID: 27826553 DOI: 10.21037/hbsn.2016.05.03] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
70 Na K, Jeong SK, Lee MJ, Cho SY, Kim SA, Lee MJ, Song SY, Kim H, Kim KS, Lee HW. Human liver carboxylesterase 1 outperforms alpha-fetoprotein as biomarker to discriminate hepatocellular carcinoma from other liver diseases in Korean patients. Int J Cancer. 2013;133:408-415. [PMID: 23319432 DOI: 10.1002/ijc.28020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
71 Wei S, Suryani Y, Gowda GA, Skill N, Maluccio M, Raftery D. Differentiating hepatocellular carcinoma from hepatitis C using metabolite profiling. Metabolites. 2012;2:701-716. [PMID: 24957758 DOI: 10.3390/metabo2040701] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
72 Ismail MM, Morsi HK, Abdulateef NA, Noaman MK, Abou El-Ella GA. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance. Scand J Clin Lab Invest 2017;77:175-83. [PMID: 28276727 DOI: 10.1080/00365513.2017.1286684] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
73 Fujiwara M, Kwok S, Yano H, Pai RK. Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies. Cancer Cytopathology 2012;120:230-7. [DOI: 10.1002/cncy.21190] [Cited by in Crossref: 49] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
74 Braillon A. Is the American Association for the Study of Liver Diseases recommendation for hepatocellular carcinoma screening a cul-de-sac? World J Gastroenterol 2013; 19(21): 3369-3370 [PMID: 23745043 DOI: 10.3748/wjg.v19.i21.3369] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
75 Wu P, Dugoua JJ, Eyawo O, Mills EJ. Traditional Chinese Medicines in the treatment of hepatocellular cancers: a systematic review and meta-analysis. J Exp Clin Cancer Res. 2009;28:112. [PMID: 19674474 DOI: 10.1186/1756-9966-28-112] [Cited by in Crossref: 53] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
76 Bahgat DM, Shahin RM, Makar NN, Aziz AO, Hunter SS. Reversion-Inducing-Cysteine-Rich Protein With Kazal Motifs (RECK) Gene Single Nucleotide Polymorphism With Hepatocellular Carcinoma: A Case-Control Study. J Clin Lab Anal 2016;30:36-40. [PMID: 25278269 DOI: 10.1002/jcla.21806] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
77 Li B, Li B, Guo T, Sun Z, Li X, Li X, Chen L, Zhao J, Mao Y. Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of α-fetoprotein, α-fetoprotein-L3, des-γ-carboxy prothrombin, and Golgi protein 73. Oncotarget 2017;8:80521-30. [PMID: 29113322 DOI: 10.18632/oncotarget.19298] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
78 Huang TM, Luo GR. Mechanisms underlying spontaneous regression of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2012; 20(21): 1939-1948 [DOI: 10.11569/wcjd.v20.i21.1939] [Reference Citation Analysis]
79 Yen CJ, Kudo M, Lim HY, Hsu CH, Vogel A, Brandi G, Cheng R, Nitu IS, Abada P, Hsu Y, Zhu AX, Kang YK. Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies. Liver Cancer 2020;9:440-54. [PMID: 32999870 DOI: 10.1159/000506946] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
80 Kim JU, Shariff MIF, Crossey MME, Gomez-Romero M, Holmes E, Cox IJ, Fye HKS, Njie R, Taylor-Robinson SD. Hepatocellular carcinoma: Review of disease and tumor biomarkers. World J Hepatol 2016; 8(10): 471-484 [PMID: 27057305 DOI: 10.4254/wjh.v8.i10.471] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
81 Memon WA, Haider Z, Beg MA, Idris M, Akhtar TU, Idris S. Diagnosis of hepatoma using grayscale and Doppler ultrasound in patients with chronic liver disease. Int J Gen Med 2011;4:751-4. [PMID: 22114519 DOI: 10.2147/IJGM.S25170] [Reference Citation Analysis]
82 Ahn YH, Shin PM, Oh NR, Park GW, Kim H, Yoo JS. A lectin-coupled, targeted proteomic mass spectrometry (MRM MS) platform for identification of multiple liver cancer biomarkers in human plasma. J Proteomics 2012;75:5507-15. [PMID: 22789673 DOI: 10.1016/j.jprot.2012.06.027] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 5.1] [Reference Citation Analysis]
83 Luo LM, Xia H, Shi R, Zeng J, Liu XR, Wei M. The association between aquaporin-1 expression, microvessel density and the clinicopathological features of hepatocellular carcinoma. Oncol Lett 2017;14:7077-84. [PMID: 29344137 DOI: 10.3892/ol.2017.7106] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
84 Woeste MR, Geller AE, Martin RCG 2nd, Polk HC Jr. Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. Ann Surg Oncol 2021;28:1499-510. [PMID: 33393028 DOI: 10.1245/s10434-020-09414-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Morana G, Grazioli L, Kirchin MA, Bondioni MP, Faccioli N, Guarise A, Schneider G. Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol. 2011;46:225-239. [PMID: 21102346 DOI: 10.1097/rli.0b013e3181feee3a] [Cited by in Crossref: 60] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
86 Finelli C, Tarantino G. Should visceral fat, strictly linked to hepatic steatosis, be depleted to improve survival? Hepatol Int 2013;7:413-28. [DOI: 10.1007/s12072-012-9406-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
87 Patel M, Shariff MI, Ladep NG, Thillainayagam AV, Thomas HC, Khan SA, Taylor-Robinson SD. Hepatocellular carcinoma: diagnostics and screening. J Eval Clin Pract 2012;18:335-42. [PMID: 21114800 DOI: 10.1111/j.1365-2753.2010.01599.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
88 Huo L, Wu Z, Zhuang H, Fu Z, Dang Y. Dual time point C-11 acetate PET imaging can potentially distinguish focal nodular hyperplasia from primary hepatocellular carcinoma. Clin Nucl Med. 2009;34:874-877. [PMID: 20139820 DOI: 10.1097/rlu.0b013e3181bed06e] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
89 Muros-ortega M, Díaz-carrasco MS, Capel A, Calleja MÁ, Martínez F. Effectiveness and safety of doxorubicin loaded beads in hepatocellular carcinoma. Int J Clin Pharm 2013;35:1105-12. [DOI: 10.1007/s11096-013-9831-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
90 Riener MO. [Diagnosis of tumours of the liver and the biliary tract: new tissue and serum markers]. Pathologe 2011;32 Suppl 2:304-9. [PMID: 21814862 DOI: 10.1007/s00292-011-1467-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
91 Kim KH, Kim JY, Yoo JS. Mass spectrometry analysis of glycoprotein biomarkers in human blood of hepatocellular carcinoma. Expert Review of Proteomics 2019;16:553-68. [DOI: 10.1080/14789450.2019.1626235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
92 Mehinovic L, Islamagic E, Husic-Selimovic A, Kurtovic-Kozaric A, Vukobrat-Bijedic Z, Suljevic D. Evaluation of Diagnostic Efficiency of Alpha-Fetoprotein in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: Single-Center Experience. Open Access Maced J Med Sci 2018;6:1668-73. [PMID: 30337985 DOI: 10.3889/oamjms.2018.344] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
93 Matsubara M, Shiraha H, Kataoka J, Iwamuro M, Horiguchi S, Nishina S, Takaoka N, Uemura M, Takaki A, Nakamura S. Des-γ-carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:1602-1608. [PMID: 22554292 DOI: 10.1111/j.1440-1746.2012.07173.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
94 Kawaoka T, Aikata H, Kan H, Fujino H, Fukuhara T, Kobayashi T, Naeshiro N, Miyaki D, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Chayama K. Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib: Sorafenib for HCC with extrahepatic metastasis. Hepatol Res 2014;44:1320-8. [DOI: 10.1111/hepr.12307] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]